盘点:膀胱癌近期重要研究进展汇总

2017-08-12 MedSci MedSci原创

膀胱癌在美国的男女性最常见恶性肿瘤中分别居第4位和第9位,去年有超过1.5万人死于这一疾病。膀胱癌的病因、诊断及治疗一直也是研究的重点,这里梅斯小编整理了近期关于膀胱癌的重要研究进展与大家一同分享。【1】新的药物可有效对抗耐药型膀胱癌近日,来自哥伦比亚大学的一项新的研究发现小鼠动物实验中,一种基于疟疾寄生虫蛋白质而合成的药物可阻止对化疗耐药的膀胱癌肿瘤的生长,这一发现或可为对当前标准治疗无效果的膀

膀胱癌在美国的男女性最常见恶性肿瘤中分别居第4位和第9位,去年有超过1.5万人死于这一疾病。膀胱癌的病因、诊断及治疗一直也是研究的重点,这里梅斯小编整理了近期关于膀胱癌的重要研究进展与大家一同分享。

【1】新的药物可有效对抗耐药型膀胱癌

近日,来自哥伦比亚大学的一项新的研究发现小鼠动物实验中,一种基于疟疾寄生虫蛋白质而合成的药物可阻止对化疗耐药的膀胱癌肿瘤的生长,这一发现或可为对当前标准治疗无效果的膀胱癌患者带来新的治疗方案,该研究中所发现的疟疾寄生虫蛋白是一种名为VAR2CSA的蛋白,这种蛋白通常在疟原虫中发现,可借助此蛋白将抗癌药物输送至肿瘤中。研究人员
将VAR2CSA疟疾蛋白特定结合域与三细胞毒性化合物结合,然后将其应用于小鼠模型以观察效果,结果发现实验组80%的小鼠存活期超过70天,而未经治疗的对照组小鼠则未有此发现。表明,该研究发现此类基于疟疾寄生虫蛋白质的药物可有效治疗小鼠化学耐药型膀胱癌。目前,研究人员正在研究批量生产此种药物以用于临床试验。

【2】喝咖啡能降低膀胱癌风险


美国的一项前瞻性研究考察了咖啡摄入与胆囊癌风险的相关性。结果表明,咖啡摄入可降低胆石症风险,与胆囊癌风险的增加强烈相关。为此,研究人员在一项前瞻性队列研究中考察咖啡摄入与膀胱癌发病率之间是否也相关。结果发现,与每天摄入1杯或更少的人相比,每天摄入2杯者、3杯者、消耗4杯或更多者其膀胱癌的发病风险降低。

【3】腓骨蛋白-3可以促进肌肉侵入性膀胱癌


尿路上皮癌是膀胱癌中最为常见的类型,并且可以分为非肌肉侵入性(Ta-T1)或者肌肉侵入性(≥T2)两种类型。最近,有研究人员有研究人员鉴定了膀胱癌T1和T2类型的差异表达基因,并确认膀胱癌发展或者侵入的关键调控子。该综合法研究寻找到了一个细胞外基质糖蛋白,腓骨蛋白-3(FBLN3 or EFEMP1),并在T2对比T1膀胱癌,侵入性疾病对比非侵入性疾病中高表达。另外,研究人员还发现,与上述研究发现一致,腓骨蛋白-3的表达水平与几种膀胱癌细胞系的侵入能力有关,并且腓骨蛋白-3表达水平的调控可以影响其侵入能力。腓骨蛋白-3在膀胱癌细胞系中的敲除可以减少MIBCs在小鼠原位膀胱癌模型中的发生率,并且可以减少类胰岛素生长因子结合蛋白-5(IGFBP5)的表达。而IGFBP5在这些细胞系中的恢复可以修复其侵入和移植能力。

【4】丝裂霉素C即刻膀胱灌注治疗非肌层浸润性膀胱癌

膀胱肿瘤电切术(TURBT)后立即行单次化疗药灌注治疗非肌层浸润性膀胱癌(NMIBC)的疗效仍存在争议。对于术后即刻灌注后的辅助灌注,其疗效证据更是稀缺。为了比较NMIBC患者TURBT术后24h内丝裂霉素C(MMC)灌注和术后2周行灌注(带或者不带辅助滴注)的疗效。研究者进行了一项包含2243例患者的前瞻性多中心随机对照研究。结果表明,独立于辅助灌注,术后即刻单次灌注能够明显降低NMIBC患者的复发风险。

【5】非侵入性预测膀胱癌术后复发

膀胱尿路上皮癌(UBC)的特点之一是其复发风险较高。现有的病患监测手段是侵入性的膀胱镜检查或敏感性低的非肌层浸润性膀胱癌尿细胞学检查(NMIBC)。研究表明端粒酶逆转录酶(TERT)激活是膀胱尿路上皮癌的突变启动子。近日研究人员就端粒酶逆转录酶在膀胱尿路上皮癌预后检测中的应用进行了考察。结果显示,研究总的敏感性为80.5%,特异性89.8%并且可排除炎症或感染的影响。尿样中的TERT是可靠动态的膀胱尿路上皮癌复发预测指标。
表明尿样中的端粒酶逆转录酶突变测试是膀胱尿路上皮癌复发的早期风险预测指标。

【6】血浆和尿液突变体DNA与肌肉侵入性膀胱癌临床结局相关


肌肉侵入性膀胱癌(MIBC)具有着不良预后的特征。同时,病人可以在新辅助治疗中(NAC)获得6%的总生存率提高,但是许多病人对该疗法并无响应。体液突变DNA(mutDNA)也许可以进行治疗失败的非侵入性鉴定。最近,有研究人员收集了248份液体活检样本,包括了血浆、细胞团(UCP)和离心过尿液的上清液(USN),并且这些样本来自17名经历过NAC的病人。结果发现,在NAC前血浆中、UCP中和USN样本中,分别有35.3%、47.1%和52.9%的样本检测到了MutDNA,并且尿液样本含有更高水平的mutDNA。值得关注的是,在NAC治疗中持续进行mutDNA检测可以预测疾病复发,表现出了它作为一个化疗响应的一个早期生物标记潜力。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=237496, encodeId=212523e4967c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Aug 26 23:43:22 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233705, encodeId=74b9233e0516, content=谢谢分享。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 15 07:28:32 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233559, encodeId=03352335594b, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Aug 14 21:16:09 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380841, encodeId=e3c0138084101, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 14 05:08:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233242, encodeId=598c233242b2, content=与每天摄入1杯或更少的人相比,每天摄入2杯者、3杯者、消耗4杯或更多者其膀胱癌的发病风险降低。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sun Aug 13 20:39:05 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233020, encodeId=225723302095, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:38 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232962, encodeId=9a8a23296292, content=受教了涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Aug 12 22:08:59 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232914, encodeId=c7f7232914b1, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sat Aug 12 17:49:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-26 虈亣靌

    学习了受益匪浅

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=237496, encodeId=212523e4967c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Aug 26 23:43:22 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233705, encodeId=74b9233e0516, content=谢谢分享。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 15 07:28:32 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233559, encodeId=03352335594b, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Aug 14 21:16:09 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380841, encodeId=e3c0138084101, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 14 05:08:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233242, encodeId=598c233242b2, content=与每天摄入1杯或更少的人相比,每天摄入2杯者、3杯者、消耗4杯或更多者其膀胱癌的发病风险降低。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sun Aug 13 20:39:05 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233020, encodeId=225723302095, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:38 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232962, encodeId=9a8a23296292, content=受教了涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Aug 12 22:08:59 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232914, encodeId=c7f7232914b1, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sat Aug 12 17:49:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-15 doctorJiangchao

    谢谢分享。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=237496, encodeId=212523e4967c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Aug 26 23:43:22 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233705, encodeId=74b9233e0516, content=谢谢分享。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 15 07:28:32 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233559, encodeId=03352335594b, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Aug 14 21:16:09 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380841, encodeId=e3c0138084101, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 14 05:08:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233242, encodeId=598c233242b2, content=与每天摄入1杯或更少的人相比,每天摄入2杯者、3杯者、消耗4杯或更多者其膀胱癌的发病风险降低。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sun Aug 13 20:39:05 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233020, encodeId=225723302095, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:38 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232962, encodeId=9a8a23296292, content=受教了涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Aug 12 22:08:59 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232914, encodeId=c7f7232914b1, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sat Aug 12 17:49:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-14 虈亣靌

    学习一下谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=237496, encodeId=212523e4967c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Aug 26 23:43:22 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233705, encodeId=74b9233e0516, content=谢谢分享。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 15 07:28:32 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233559, encodeId=03352335594b, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Aug 14 21:16:09 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380841, encodeId=e3c0138084101, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 14 05:08:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233242, encodeId=598c233242b2, content=与每天摄入1杯或更少的人相比,每天摄入2杯者、3杯者、消耗4杯或更多者其膀胱癌的发病风险降低。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sun Aug 13 20:39:05 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233020, encodeId=225723302095, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:38 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232962, encodeId=9a8a23296292, content=受教了涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Aug 12 22:08:59 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232914, encodeId=c7f7232914b1, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sat Aug 12 17:49:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=237496, encodeId=212523e4967c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Aug 26 23:43:22 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233705, encodeId=74b9233e0516, content=谢谢分享。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 15 07:28:32 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233559, encodeId=03352335594b, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Aug 14 21:16:09 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380841, encodeId=e3c0138084101, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 14 05:08:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233242, encodeId=598c233242b2, content=与每天摄入1杯或更少的人相比,每天摄入2杯者、3杯者、消耗4杯或更多者其膀胱癌的发病风险降低。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sun Aug 13 20:39:05 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233020, encodeId=225723302095, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:38 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232962, encodeId=9a8a23296292, content=受教了涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Aug 12 22:08:59 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232914, encodeId=c7f7232914b1, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sat Aug 12 17:49:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-13 随梦飞扬

    与每天摄入1杯或更少的人相比,每天摄入2杯者、3杯者、消耗4杯或更多者其膀胱癌的发病风险降低。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=237496, encodeId=212523e4967c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Aug 26 23:43:22 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233705, encodeId=74b9233e0516, content=谢谢分享。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 15 07:28:32 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233559, encodeId=03352335594b, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Aug 14 21:16:09 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380841, encodeId=e3c0138084101, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 14 05:08:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233242, encodeId=598c233242b2, content=与每天摄入1杯或更少的人相比,每天摄入2杯者、3杯者、消耗4杯或更多者其膀胱癌的发病风险降低。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sun Aug 13 20:39:05 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233020, encodeId=225723302095, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:38 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232962, encodeId=9a8a23296292, content=受教了涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Aug 12 22:08:59 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232914, encodeId=c7f7232914b1, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sat Aug 12 17:49:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-13 130****4638

    学习了受益匪浅

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=237496, encodeId=212523e4967c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Aug 26 23:43:22 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233705, encodeId=74b9233e0516, content=谢谢分享。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 15 07:28:32 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233559, encodeId=03352335594b, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Aug 14 21:16:09 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380841, encodeId=e3c0138084101, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 14 05:08:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233242, encodeId=598c233242b2, content=与每天摄入1杯或更少的人相比,每天摄入2杯者、3杯者、消耗4杯或更多者其膀胱癌的发病风险降低。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sun Aug 13 20:39:05 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233020, encodeId=225723302095, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:38 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232962, encodeId=9a8a23296292, content=受教了涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Aug 12 22:08:59 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232914, encodeId=c7f7232914b1, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sat Aug 12 17:49:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-12 1e1263e3m20(暂无匿称)

    受教了涨知识了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=237496, encodeId=212523e4967c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Aug 26 23:43:22 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233705, encodeId=74b9233e0516, content=谢谢分享。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 15 07:28:32 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233559, encodeId=03352335594b, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Aug 14 21:16:09 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380841, encodeId=e3c0138084101, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Aug 14 05:08:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233242, encodeId=598c233242b2, content=与每天摄入1杯或更少的人相比,每天摄入2杯者、3杯者、消耗4杯或更多者其膀胱癌的发病风险降低。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sun Aug 13 20:39:05 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233020, encodeId=225723302095, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:38 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232962, encodeId=9a8a23296292, content=受教了涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Aug 12 22:08:59 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232914, encodeId=c7f7232914b1, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sat Aug 12 17:49:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-12 三生有幸9135

    学习一下谢谢分享

    0

相关资讯

Eur Uro:导致根治性膀胱癌切除术费用差异的因素分析。

肌层浸润性膀胱癌(BCa)行根治性膀胱切除术(RC)后,有严重并发症、住院天数增加、再住院的潜在可能。尽管关于这些结果的变化已经有很多描述,但是影响费用的决定性因素尚未有清晰的描述。

Sci Rep: 在膀胱癌中,微卫星RNAs具有预后意义

最近,有研究人员系统性的回顾了关于调查不同微卫星RNAs在膀胱癌(BC)中的预后意义的研究文献。他们系统性的搜索了PubMed、Science网站和Embase数据库来鉴定到2016年3月的相关研究。在筛选之后,共有26个研究包括了2753名病人包含在该研究中。调查发现,这些文献的结果表明许多miRs表达异常也许可以对患有BC的病人进行预后的预测。至少两个研究中被报道了6个miRs(miR-21、

Oncotarget :EZH2过度表达和伤口渗出液使膀胱癌细胞化疗敏感性变差

膀胱癌是发生在膀胱黏膜上的恶性肿瘤,是泌尿系统最常见的恶性肿瘤,是全身十大常见肿瘤之一,也占我国泌尿生殖系肿瘤发病率的第一位。

Sci Rep:在肌肉侵入性膀胱癌中,血浆和尿液突变体DNA与临床结果的关系

肌肉侵入性膀胱癌(MIBC)具有着不良预后的特征。同时,病人可以在新辅助治疗中(NAC)获得6%的总生存率提高,但是许多病人对该疗法并无响应。体液突变DNA(mutDNA)也许可以进行治疗失败的非侵入性鉴定。最近,有研究人员收集了248份液体活检样本,包括了血浆、细胞团(UCP)和离心过尿液的上清液(USN),并且这些样本来自17名经历过NAC的病人。另外,在mutDNA中,研究人员利用带标签的扩

Oncotarget:DEPDC1在鼻咽癌细胞周期进程和动力学中扮演的角色。

含DEP结构域的蛋白质1 (DEPDC1) ,一种新发现的癌症和细胞周期相关基因,已被证实为膀胱癌治疗的新靶点。然而,DEPDC1在鼻咽癌中的相关功能和治疗潜力尚不清楚。研究者在前期研究中发现:DEPDC1在鼻咽癌组织中的表达,无论在mRNA还是蛋白质水平,都较正常或非肿瘤组织高。

Clin Cancer Res:科学家鉴定出一条人膀胱癌干细胞干性维持的新通路

中国科学院微生物研究所温廷益研究组和中国科学院生物物理研究所副研究员李翀等通过合作鉴定了人膀胱癌干细胞一条新的干性维持通路——KMT1A-GATA3-STAT3信号通路。